Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDx, Bayer Partner on NGS-Based Companion Diagnostic Test Development

NEW YORK ─ Life sciences firm Bayer and genomic analysis company ArcherDx on Thursday announced a global collaboration for the development and commercialization of a next-generation sequencing-based companion diagnostic test for Bayer's Vitrakvi (larotrectinib), which targets cancers with fusions in neurotrophic receptor tyrosine kinase (NTRK) genes.

The primary objective of the collaboration is to broaden patient access to comprehensive genomic testing that includes NTRK1, NTRK2, and NTRK3 gene fusions and to improve identification of appropriate treatment options for patients with TRK fusion cancer, the firms said.

Boulder, Colorado-based ArcherDx and Leverkusen, Germany-based Bayer said they anticipate seeking approval for the CDx in markets including the European Union, US, and Japan.

Financial and other terms of the collaboration were not disclosed.

The companion diagnostic test will allow local laboratories to provide referring physicians with potentially actionable genomic information so that appropriate patients can be matched to specific therapeutic options based on their genomic findings, the firms said.

"A kit-based CDx that is tumor agnostic and detects all NTRK gene fusions will enable high-quality genomic testing to be deployed in regional and community settings, where 85 percent of cancer patients receive care," Jason Myers, ArcherDx CEO and cofounder, said in a statement. "For these patients, our technology provides RNA-based profiling for the detection of actionable fusions across known and novel NTRK fusion partners."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.